Using endophenotypes to examine molecules related to candidate genes as novel therapeutics: The “endophenotype-associated surrogate endpoint (EASE)” concept

•This article proposed a new concept of an “endophenotype-associated surrogate endpoint”.•The concept is a combination of “endophenotype” and “surrogate endpoint”.•The advantages are expected in both drug development and uncovering pathogenesis.•Significant effect is likely to be observed with small...

Full description

Saved in:
Bibliographic Details
Published in:Neuroscience research 2015-10, Vol.99, p.1-7
Main Author: Yamasue, Hidenori
Format: Article
Language:English
Subjects:
Animals
Autism spectrum disorder
Biomarkers - analysis
Biomarkers - metabolism
Dopamine
Endophenotypes - metabolism
Genetic Predisposition to Disease
Genotype
Humans
Mental Disorders - diagnosis
Mental Disorders - genetics
Neuroimaging
Obsessive–compulsive disorder
Oxytocin
Schizophrenia
Serotonin
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•This article proposed a new concept of an “endophenotype-associated surrogate endpoint”.•The concept is a combination of “endophenotype” and “surrogate endpoint”.•The advantages are expected in both drug development and uncovering pathogenesis.•Significant effect is likely to be observed with smaller sample and shorter period.•Elucidating biological mechanisms underlying novel treatments can be expected. In this article, a new concept of an “endophenotype-associated surrogate endpoint (EASE)” is proposed. To examine effect of a novel therapeutic molecule on a target phenotype of a genotype associated with the molecule, state-dependent aspect of an endophenotype can be used as a surrogate endpoint. Desired characteristics for EASE are (1) a close relationship to the endophenotype associated with therapeutics, (2) longitudinal changes in illness severity, while the original “endophenotype” is primarily state independent, (3) a physical sign or laboratory measurement that occurs in association with a pathological process and has putative diagnostic and/or prognostic utility, and (4) serves as a substitute for a clinically meaningful endpoint. Advantages are expected for both surrogate endpoints in drug development and endophenotypes in uncovering pathogenesis. EASE are closer to molecules than clinically meaningful endpoints and can respond to administration of the molecule in a more direct manner. Therefore, a statistically significant effect is likely to be observed in clinical trials with smaller sample sizes and shorter durations. As with endophenotypes, reduced heterogeneity might be expected especially in heterogeneous syndromes such as psychiatric disorders. Potential interactions (e.g., elucidating biological mechanisms underlying novel treatments) can be further expected.
ISSN:0168-0102
1872-8111
DOI:10.1016/j.neures.2015.05.007